title: Expression of Bcl-2 but not Bax or p53 correlates with in vitro resistance to a series of anticancer drugs in breast carcinoma.
abstract: Programmed cell death is an important determinant of the response to chemotherapy. Among the factors controlling this process, a significant role is played by bcl-2, bax and p53. The in vitro chemosensitivity of the 177 breast carcinomas was assessed by the histoculture drug response assay (HDRA) using mitomycin C (MMC), 5-fluorouracil (5-Fu), adriamycin (ADM), cisplatin (CDDP), and cyclophosphamide (CPA). The susceptibility of Bcl-2-negative tumors to all the drugs killing was significantly higher than that of Bcl-2-positive tumors. No relationship between Bax or p53 immunoreactivity and sensitivity for any of anticancer drugs studied was demonstrated. Immunohistochemical results regarding Bcl-2 are promising in the evaluation of the sensitivity of cancer cells to a series of anticancer drugs and might be therapeutically useful as an indicator of response to adjuvant chemotherapy for breast cancer.
authors.affiliation: Department of Surgery, Affiliated Kihoku Hospital, Wakayama Medical College, Wakayama City, Japan. yang-qf@mail.wakayama-med.ac.jp
authors.forename: Q F
authors.initials: QF
authors.lastname: Yang
authors.forename: T
authors.initials: T
authors.lastname: Sakurai
authors.forename: G
authors.initials: G
authors.lastname: Yoshimura
authors.forename: L
authors.initials: L
authors.lastname: Shan
authors.forename: T
authors.initials: T
authors.lastname: Suzuma
authors.forename: T
authors.initials: T
authors.lastname: Tamaki
authors.forename: T
authors.initials: T
authors.lastname: Umemura
authors.forename: Y
authors.initials: Y
authors.lastname: Kokawa
authors.forename: Y
authors.initials: Y
authors.lastname: Nakamura
authors.forename: M
authors.initials: M
authors.lastname: Nakamura
authors.forename: W
authors.initials: W
authors.lastname: Tang
authors.forename: H
authors.initials: H
authors.lastname: Utsunomiya
authors.forename: I
authors.initials: I
authors.lastname: Mori
authors.forename: K
authors.initials: K
authors.lastname: Kakudo
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D018275:Carcinoma, Lobular / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D015151:Immunoblotting; D007124:Immunoenzyme Techniques; D011518:Proto-Oncogene Proteins / Q000378:metabolism*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism*; D018709:Statistics, Nonparametric; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D051028:bcl-2-Associated X Protein
chemical_list: D000970:Antineoplastic Agents; C494826:BAX protein, human; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D051028:bcl-2-Associated X Protein